Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101569 · ClinicalTrials.gov registry record · Phase 3
Aripiprazole Oral Acceptability Trial
A Phase 3 study of Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
- 7
- Study locations
NCT00101569 is a Phase 3 study of Schizophrenia that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 59 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT00101569, a Phase 3 study of Schizophrenia, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.
Conditions Studied
Interventions
- DRUG Aripiprazole
Study Locations (7)
California
- Local Institution - Anaheim
- Local Institution - National City
Florida
- Local Institution - North Miami Beach
Kansas
- Local Institution - Overland Park
New York
- Local Institution - Staten Island
Oklahoma
- Local Institution - Oklahoma City
Virginia
- Local Institution - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00101569
The ClinicalTrials.gov registry entry for NCT00101569 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00101569 reports 7 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT00101569 about?
NCT00101569 is a clinical study titled "Aripiprazole Oral Acceptability Trial". The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.
What is the current status of trial NCT00101569?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2004-03. Estimated completion is 2005-03.
What conditions does trial NCT00101569 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00101569?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00101569?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00101569 being conducted?
This trial has 7 study locations across California, Florida, Kansas, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.